실시간
FierceBiotechFoundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic targetFierceBiotechIn a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancerFierceBiotechRay Therapeutics shines a light on $125M round targeting genetic eye therapyFierceBiotechTortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from AsiaFierceBiotechPfizer's strategy head Andrew Baum to step down following brief tenure: reportsLonza NewsSimulations Plus (SLP) Partners with FDA and Lonza for Drug Perf - GuruFocusLonza NewsSimulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks fo - PharmiWeb.comLonza NewsSimulations Plus partners with Lonza and FDA on drug formulation research - Investing.comBioWorldJapanese researchers report new μ-opioid receptor antagonistsBioWorldIncyte discloses new TYK2 and/or JAK1 inhibitorsBioWorldInsilico Medicine divulges new NLRP3 inflammasome inhibitorsBioWorldNeolaia synthesizes new CD38 inhibitors
PLoS Biology 2025년 12월 3일

Subcellular proteomics of the protist <i>Paradiplonema papillatum</i> reveals the digestive capacity of the cell membrane and the plasticity of peroxisomes across euglenozoans

Subcellular proteomics of the protist Paradiplonema papillatum reveals the digestive capacity of the cell membrane and the plasticity of peroxisomes across eugl...

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.